论文部分内容阅读
目的观察替格瑞洛对冠心病患者经皮冠状动脉介入治疗(PCI)术后凝血功能的影响,为冠心病临床治疗提供参考。方法选取2013年1月-2015年1月成功完成PCI手术的冠心病患者150例,随机分为2组,每组75例,观察组采用替格瑞洛治疗,对照组采用氯吡格雷治疗,比较2组患者凝血功能、血小板凝聚率及不良反应。结果治疗前2组患者凝血酶原时间(PT)、活化部分凝血酶时间(APTT)、凝血酶时间(TT)以及纤维蛋白原(FIB)比较差异均无统计学意义(P>0.05);治疗后2组凝血功能均较治疗前明显改善,且观察组优于对照组,差异均有统计学意义(P<0.05)。治疗前2组患者血小板凝聚率比较差异无统计学意义(P>0.05),治疗后2组患者血小板凝聚率均低于治疗前,且观察组明显低于对照组,差异均有统计学意义(P<0.05)。观察组不良反应总发生率为10.7%略高于对照组的8.0%,但差异无统计学意义(P>0.05)。结论替格瑞洛对冠心病PCI术后患者具有较强效的抑制血小板聚集作用,减少血液凝聚,避免血栓的形成,增加患者安全性,值得临床推广应用。
Objective To observe the effect of ticagrelor on coagulation function after percutaneous coronary intervention (PCI) in patients with coronary heart disease (CHD) and provide a reference for the clinical treatment of coronary heart disease. Methods 150 patients with coronary heart disease who underwent PCI during January 2013 to January 2015 were randomly divided into 2 groups (n = 75 each). The patients in the observation group were treated with ticagrelor, the patients in the control group were treated with clopidogrel, The coagulation function, platelet aggregation rate and adverse reactions in two groups were compared. Results There were no significant differences in prothrombin time (PT), APTT, TT and fibrinogen (FIB) between the two groups before treatment (P> 0.05) The coagulation function of the latter two groups were significantly improved compared with that before treatment, and the observation group was better than the control group, the differences were statistically significant (P <0.05). There was no significant difference in platelet aggregation rate between the two groups before treatment (P> 0.05). The platelet aggregation rate in the two groups after treatment was lower than that before treatment, and the observation group was significantly lower than the control group (P> 0.05) P <0.05). The total incidence of adverse reactions in the observation group was 10.7% slightly higher than that in the control group (8.0%), but the difference was not statistically significant (P> 0.05). Conclusion Ticagrelor has a potent inhibitory effect on platelet aggregation, reduces blood coagulation, avoids the formation of thrombus and increases the safety of patients with coronary heart disease after PCI. It is worthy of clinical application.